UNSPSC 51281610: Dibekacin

This classification denotes an aminoglycoside antibiotic with the molecular formula C18H37N5O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 45ZFO9E525, chemically known as 3,4-dideoxykanamycin b but generally known as dibekacin, which bears US NIH Compound Identifier 3021. European Medicines Agency schedules Dibekacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07072MIG.

UNSPSC 51281610 Dibekacin is a Commodity code nominally designating a specific aminoglycoside antibiotic, but recent state and local solicitations tagged with this code show procurement activity focused on a much broader range of pharmaceutical products and medical supplies rather than dibekacin itself. The opportunities reflect purchasing of naloxone and drug deactivation systems for emergency response and community health; medical and first aid supplies including respiratory equipment, cardiac monitoring devices, and consumables for fire-rescue operations; generic multi-source pharmaceuticals and over-the-counter products for statewide distribution; and exploratory contracting for direct-to-manufacturer prescription fulfillment programs. The issuing bodies span county health departments, state health and human services agencies, municipal purchasing departments, and multistate cooperative purchasing alliances. The code shows activity across state agencies in Texas and Minnesota, county-level procurement in Florida, and city procurement in Tampa, reflecting a mix of health department, fire-rescue, and statewide pharmacy benefit procurements.

Recent opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (posted June 30, 2026; due July 26, 2023), the City of Tampa's IFB for medical and first aid supplies for the Fire Department Rescue Division including 169 line items of emergency response consumables with an estimated contract value of $700,000.00 (posted March 25, 2026; due March 13, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance's RFP to establish multiple contracts for generic pharmaceuticals and OTC products with proposals due March 26, 2026 and awards effective July 1, 2026. The Minnesota RFP requires vendor compliance with cGMP, Drug Supply Chain Security Act certification, and relationships with authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson. The code also reflects exploratory activity from the Texas Health and Human Services Commission's RFI regarding direct-to-manufacturer prescription programs (posted April 3, 2026), which seeks vendor capacity to establish relationships outside traditional pharmacy benefit manager and group purchasing organization channels.